Credit Suisse Starts Ra Pharma (RARX) at Outperform

November 21, 2016 6:57 AM EST
Get Alerts RARX Hot Sheet
Price: $14.77 +5.12%

Rating Summary:
    3 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 30 | Down: 30 | New: 23
Trade RARX Now!
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

Credit Suisse initiates coverage on Ra Pharma (NASDAQ: RARX) with a Outperform rating and a price target of $19.00.

Analyst Kennen MacKay commented, "We view RA101495 as an attractive drug candidate for patients with paroxysmal nocturnal hemoglobinuria (PNH) with potential to capture >30% market share in patients with unmet need despite Soliris treatment. We see RA101495 as competitive vs. Soliris based on ease of use (daily subcutaneous vs. bimonthly IV infusion) as well as potential to address unmet need in the ~33% of PNH patients with inadequate response to Soliris. We view potential for RA101495 to generate peak global sales of $837M. We see upside potential from RA101495 in other indications (MG, LN, aHUS, etc.) as well as other pipeline assets from RARX’s platform."

For an analyst ratings summary and ratings history on Ra Pharma click here. For more ratings news on Ra Pharma click here.

Shares of Ra Pharma closed at $13.29 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, New Coverage

Related Entities

Credit Suisse

Add Your Comment